Chase Ng
@cut_tt_chase
Followers
146
Following
138
Media
12
Statuses
70
Urology ST4 @ NCE London | RSM Urology Scholar | Clinical Research Fellow @ IP & KCL | Special interest in uro-oncology and implementation science
London, England
Joined November 2022
The medium-term oncological safety of MRI-led prostate cancer diagnostic pathway is unclear. We followed up 1266 patients and summarised our findings into 3 key messages. @IP_London @EUplatinum Read full paper for free: https://t.co/d7Ma9cUBXr
0
1
3
The medium term effectiveness of MRI-directed dx pathway in 📈 GG≥2, 📉 GG1 and 🛑 redundant biopsies. PSAD-based PSA threshold for re-referral (20%+ from initial PSA if baseline PSAD >0.12, or PSA when their PSAD reaches 0.12) is safe. 👨🏫@LondonProstate1 @TaimurShah
🚨 NEW paper @EUplatinum 🚨 5-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the #RAPID MRI-directed Prostate Cancer Diagnostic Pathway Led by @cut_tt_chase @LondonProstate1 @TaimurShah Read for free! https://t.co/YyvvThEgXj 1/4
0
1
2
📣 We’ve successfully randomised 1,645 patients to IP7-PACIFIC! RCT1️⃣ bpMRI vs mpMRI RCT2️⃣ image-fusion vs visual estimation targeting Top recruiters in October 🏆 1st – Imperial 🥈 Joint 2nd – Cumberland & St Peter’s Top total recruiters 🏆 Imperial - 346 🥈 Southend - 338
The protocol paper for the #IP7PACIFIC RCT is now available online! This trial led by our group and funded by @CR_UK will provide definitive evidence for "fast" biparametric MRI and image-fusion biopsy using a novel trial design 🚨 @NikhilMayor
https://t.co/gdXNqWThLb
0
4
11
Blink and you’ll miss it! Make sure you’re on time for registration.
It’s less than 24 hours to registration! Scan the QR code on the flyer or tap on the link below to register: https://t.co/TREU958IZM The form will only be live from 09:00 tomorrow!
0
0
0
The STARS Urology ST3 Interview Course 2026 is back! Registration will go live @ 09:00 31/10/25. There are very limited spaces so make sure to sign up as soon as possible! @BSoT_UK
0
6
8
Rpt TURBT for NMIBC ⬆️ morbidity, cost, carbon footprint Could office-based TULA be a safe de-escalation strategy? TULA vs TURBT (EORTC risk-matched) 📈Higher recurrence 📊Similar progression 📉Low muscle invasion 👫Good OS&CSS @imperialurology
https://t.co/GDFr85WMJo
bjui-journals.onlinelibrary.wiley.com
Introduction Elderly and comorbid patients with non-muscle invasive bladder cancer (NMIBC) often undergo repeated transurethral resection of bladder tumour (TURBT) under general anaesthesia. Transu...
0
0
1
Timely update on surgical health policy; progress has been made but there are still multiple, interlocking issues. Will the new global health architecture address these? https://t.co/E3cBAQqQt1
@WHO @WorldBank
0
3
5
Zambian national cancer registry, active global collaboration and mindful adoption of technology are 3 facilitators to build on. Our recommended priorities and strategies tiered by individual, organisational and institutional stakeholders ⬇️
0
1
2
We backed our systematic review with a consensus meeting to develop Zambia-specific cancer research capacity-building priorities and strategies. Implementation is key to decolonise research ecosystem and decentralise cancer services in Zambia. #ecancer
https://t.co/MlByTzMT4O
ecancer.org
Mapping the cancer research landscape across Zambia: evidence to support national cancer control planning Susan Msadabwe1†, Peng Yun Ng2†,a, Richard Sulliv
1
0
5
Our figure summarising the quality indicators and patient outcome measures identified across all domains of palliative care
0
0
2
Key findings of our systematic review of quality indicators (QI) and patient outcome measures (POM) for pal care in cancer: 1. Lack of standardisation of QIs esp in structure and outcome of care 2. A standardised QI and POM repository is required https://t.co/IpheYQxira
ecancer.org
Quality indicators and patient outcome measures for palliative care in cancer patients: a systematic review Chase Peng Yun Ng1, Moira Hegyi1, Grant Lewison
1
0
3
Fantastic overview of diagnostic and therapeutic strategies in radiorecurrent prostate cancer by @TaimurShah Key takeaways - MRI highly sensitive for local disease (even more so with PSMA PET/CT) & focal therapy as effective as RP in the salvage setting #BAUS25
0
5
12
Brilliant prostate cancer abstract session this morning with 4️⃣ presentations from Team IP at #BAUS25 Huge breadth covered including MRI diagnostics, focal therapy, intraoperative margin assessment, and cytoreduction strategies in metastatic disease
1
4
13
@NikhilMayor presents outcomes from the first prospective, blinded assessment of #FCM with the #HistologScanner in #RadicalProstatectomy #IP8FLUORESCE
0
3
6
Next up @cut_tt_chase presents the 5 year oncological outcomes of men with initial negative #ProstateCancer investigations in the #RAPID pathway 🏃
1
4
12
1
6
26
Update of #IP7PACIFIC presented by @AJWLight at #AUA25 This will be the first trial to provide definitive evidence comparing bpMRI vs mpMRI, alongside fusion vs cognitive biopsy >1200 patients recruited across the UK - watch this space
0
4
11
In further #RAPID data, @cut_tt_chase shows that patients discharged from a pre-biopsy MRI pathway with ASAP or HGPIN do not have a greater risk of subsequent csPCa or treatment than patients discharged without #AUA25 @AJWLight
0
7
22
Building on our #IP8FLUORESCE study is #IB1LaserCOMPLETE - using ex vivo fluoresce confocal microscopy to establish muscle status in TURBT. Presented here by @Archana_GK1 Recruitment is under way - watch this space for results soon! #AUA25
0
5
10
Thank you Victor for highlighting this piece of work by @IP_London, which cements the oncological efficacy of the MRI-led RAPID prostate cancer diagnostic pathway. #LATP #mpMRI #AUA25
5-year outcomes following a negative MRI or negative biopsy for suspected prostate cancer: results from 1285 patients in the rapid assessment for prostate imaging and diagnosis (RAPID) pathway. Presented by @cut_tt_chase @KingsCollegeLon. #AUA25 written coverage by @VictorPham01
0
0
0